LEXXW - Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
(TheNewswire)
-
- New study EPIL-A21-1 will compareeffectiveness of FDA-approved Epidiolex to DehydraTECH TM -CBD for reducing seizure activity
Kelowna, British Columbia - TheNewswire - November 1, 2021 -Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms, hascommenced an important new study exploring whetherDehydraTECH TM -CBD evidences superior ability to inhibit seizure activitycompared to both generic cannabidiol (“CBD”) and Epidiolex.
Epidiolex is the first and only FDA-approved CBDmedication for the treatment of seizures associated with two rare andsevere forms of paediatric epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
Experts in respirology and neurobiology are among thetalented team assembled to conduct the study which is designed toinvestigate if DehydraTECH-CBD has similar or superior levels ofefficacy in treating seizures as does the world’s only CBD-basedseizure medication, Epidiolex. Lexaria’s seizure program has beendeveloped due to the significant gains in systemic delivery and brainuptake that Lexaria has repeatedly evidenced and announced from other studies comparing DehydraTECH-CBD withconcentration-matched controls, which it believes has potential toimprove therapeutic efficacy for a range of disease conditionsaffecting the central nervous system including epilepsy.
Epidiolex was developed by GW Pharmaceuticals plc(“GW”) and is now sold by Jazz Pharmaceuticals (“Jazz”)subsequent to the 2021 US$7.2 billion takeover of GW by Jazz.
Animal study EPIL-A21-1 has entered early-stagepreparatory work and results are expected by Q3 2022. This animalstudy is being conducted by a leading US-based independent laboratoryusing advanced DehydraTECH 2.0 formulations and is fully fundedthrough existing Lexaria resources.
In other developments, Lexaria is pleased to report itsfirst patent award for DehydraTECH in Mexico. The patent awardprotects Lexaria’s proprietary DehydraTECH for use with cannabinoidsand nicotine. The Company has also been awarded another patent inJapan for the use of DehydraTECH utilizing non-psychoactivecannabinoids, nicotine, vitamins, or non-steroidal anti-inflammatory(“NSAID”) substances. This latest patent award in Japan becomesLexaria’s 5th patent awarded in 2021. Lexaria’s patentedDehydraTECH currently benefits from 23 granted patents in thecountries of the USA, Australia, the European Union, India, Japan, andMexico. Lexaria continues to build its intellectual property portfolioin these and other countries.
About Epidiolex
Epidiolex isan FDA-approved prescription CBD available in an oral solution totreat Lennox-Gastaut syndrome and Dravet syndrome in children twoyears of age and older. Epidiolex’s effectiveness was studied inthree randomized clinical trials involving a total of 516 patients andwas shown to be effective in reducing the frequency of seizures whencompared to placebo. In September 2019,Epidiolex was approved for use in all 27 member countries of theEuropean Union.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting more effectiveoral delivery . Since 2016, DehydraTECH hasrepeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 - 2 hours tominutes, and mask unwanted tastes; and is also being evaluated fororally administered anti-viral drugs, non-steroidal anti-inflammatorydrugs (NSAIDs), and more. DehydraTECH has also evidenced an ability todeliver some drugs more effectively across the blood brain barrier.Lexaria operates a licensed in-house research laboratory and holds arobust intellectual property portfolio with 23 patents granted andover 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances or otherwise, exceptas otherwise required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.